Feedback / Questions
anti-CLDN18.2/anti-CD3 bispecific antibody - Accurus Biosci
https://www.businesswire.com/news/home/20240116135812/en/Accurus-Biosciences-and-ImmPACT-Bio-Enter-into-an-Exclusive-Global-License-Agreement-for-a-Potentially-Best-in-Class-CLDN18.2-Antibody
 
Jan 16, 2024
 
SHARE THIS
  • Print
  • Email
  • More sharing
    Reddit
    StumbleUpon
    Delicious